MedTrace Logo

Clinical Trials

NCT04847063 | RECRUITING | PHASE1
60 participants

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-10-19
Completion:
2033-12-30
Conditions
  • Peritoneal Mesothelioma
  • Peritoneal Carcinomatosis
  • Ovarian Cancer
  • Gastrointestinal Cancer
  • Appendiceal Cancer
  • Atypical Mesothelial Proliferation
  • Colorectal Cancer
Interventions
  • DRUG
  • PROCEDURE
No Results Yet
NCT04739800 | ACTIVE_NOT_RECRUITING | PHASE2
120 participants

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-06-10
Completion:
2023-01-26
Conditions
  • Fallopian Tube Mucinous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Platinum-Refractory Fallopian Tube Carcinoma
  • Platinum-Refractory Ovarian Carcinoma
  • Platinum-Refractory Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Mucinous Adenocarcinoma
  • Recurrent Fallopian Tube Transitional Cell Carcinoma
  • Recurrent Fallopian Tube Undifferentiated Carcinoma
  • Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Ovarian Mucinous Adenocarcinoma
  • Recurrent Ovarian Seromucinous Carcinoma
  • Recurrent Ovarian Transitional Cell Carcinoma
  • Recurrent Ovarian Undifferentiated Carcinoma
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Transitional Cell Carcinoma
  • Recurrent Primary Peritoneal Undifferentiated Carcinoma
  • Refractory Fallopian Tube Clear Cell Adenocarcinoma
  • Refractory Fallopian Tube Endometrioid Adenocarcinoma
  • Refractory Fallopian Tube High Grade Serous Adenocarcinoma
  • Refractory Fallopian Tube Mucinous Adenocarcinoma
  • Refractory Fallopian Tube Transitional Cell Carcinoma
  • Refractory Fallopian Tube Undifferentiated Carcinoma
  • Refractory Low Grade Fallopian Tube Serous Adenocarcinoma
  • Refractory Ovarian Clear Cell Adenocarcinoma
  • Refractory Ovarian Endometrioid Adenocarcinoma
  • Refractory Ovarian High Grade Serous Adenocarcinoma
  • Refractory Ovarian Low Grade Serous Adenocarcinoma
  • Refractory Ovarian Mucinous Adenocarcinoma
  • Refractory Ovarian Seromucinous Carcinoma
  • Refractory Ovarian Transitional Cell Carcinoma
  • Refractory Ovarian Undifferentiated Carcinoma
  • Refractory Primary Peritoneal Clear Cell Adenocarcinoma
  • Refractory Primary Peritoneal Endometrioid Adenocarcinoma
  • Refractory Primary Peritoneal High Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Transitional Cell Carcinoma
  • Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT04708418 | ACTIVE_NOT_RECRUITING | PHASE2
60 participants

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-10-15
Completion:
2026-12-31
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Melanoma of Unknown Primary
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Recurrent Cutaneous Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT04676529 | COMPLETED | PHASE1/PHASE2
43 participants

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-02-18
Completion:
2025-07-09
Conditions
  • Myelofibrosis
  • Primary Myelofibrosis (PMF)
  • Post- Essential Thrombocythemia Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis
Interventions
  • DRUG
Results Available
NCT04623541 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
194 participants

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2020-11-25
Completion:
2027-12-31
Conditions
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Richter's Syndrome
  • Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT04579224 | ACTIVE_NOT_RECRUITING | PHASE3
184 participants

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-06-28
Completion:
2030-08-15
Conditions
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Refractory Bladder Urothelial Carcinoma
  • Refractory Urothelial Carcinoma
  • Stage IV Bladder Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT04542824 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
78 participants

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2020-08-20
Completion:
2027-09-30
Conditions
  • Diffuse Large B Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Primary Mediastinal Large B Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocytic Lymphoma
Interventions
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT04444921 | ACTIVE_NOT_RECRUITING | PHASE3
205 participants

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2020-11-17
Completion:
2027-03-31
Conditions
  • Anal Basaloid Carcinoma
  • Anal Canal Cloacogenic Carcinoma
  • Metastatic Anal Squamous Cell Carcinoma
  • Recurrent Anal Squamous Cell Carcinoma
  • Stage III Anal Cancer AJCC v8
  • Stage IV Anal Cancer AJCC v8
  • Unresectable Anal Squamous Cell Carcinoma
Interventions
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT04387656 | ACTIVE_NOT_RECRUITING
1877 participants

NCI COVID-19 in Cancer Patients, NCCAPS Study

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-04
Start Date:
2020-06-05
Completion:
2024-03-20
Conditions
  • COVID-19 Infection
  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
Interventions
  • PROCEDURE
  • OTHER
No Results Yet
NCT04310007 | ACTIVE_NOT_RECRUITING | PHASE2
117 participants

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2020-07-13
Completion:
2026-12-31
Conditions
  • Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
  • Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03984448 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
363 participants

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2019-10-22
Completion:
2028-04-01
Conditions
  • Diffuse Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Double-Expressor Lymphoma
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page